| Umani ("-limu-") | Immunosoppressori: Abrilumab • Adalimumab • Anifrolumab • Atorolimumab • Avelumab • Avdoralimab • Belimumab • Bleselumab • Brodalumab • Camidanlumab tesirina • Carlumab • Cemiplimab • Dupilumab • Eldelumab • Emapalumab • Fresolimumab • Garadacimab • Golimumab • Ianalumab • Lanadelumab • Lenzilumab • Lerdelimumab • Lirentelimab • Lirilumab • Mavrilimumab • Metelimumab • Morolimumab • Namilumab • Nipocalimab •Oleclumab • Oxelumab§ • Pamrevlumab • Placulumab • Relatlimab† • Sarilumab • Sifalimumab • Tabalumab • Tezepelumab • Toripalimab • Ulocuplumab • Varlilumab
Attivazione immunitaria: Durvalumab • Ipilimumab • Nivolumab • Tremelimumab • Urelumab
Altri: Bertilimumab • Ontamalimab • Zanolimumab |
|---|
| Topo ("-limo-") | Afelimomab • Elsilimomab • Faralimomab • Gavilimomab • Inolimomab • Maslimomab • Nerelimomab • Odulimomab • Telimomab aritox • Vepalimomab • Zolimomab aritox |
|---|
| Chimerici ("-lixi-") | Andecaliximab† • Basiliximab • Clenoliximab • Galiximab • Gomiliximab • Infliximab • Keliximab • Lumiliximab • Priliximab • Teneliximab • Vapaliximab |
|---|
Umanizzato
("-lizu-") | Immunosoppressori: Apolizumab • Aselizumab • Atezolizumab • Benralizumab† • Camrelizumab† • Cedelizumab • Certolizumab pegol • Crizanlizumab • Daclizumab • Eculizumab • Efalizumab • Epratuzumab • Erlizumab • Etrolizumab† • Fontolizumab • Inebilizumab • Itolizumab • Lampalizumab† • Leronlimab • Letolizumab • Ligelizumab† • Lulizumab pegol • Mepolizumab • Mogamulizumab • Natalizumab • Ocrelizumab • Omalizumab • Ozoralizumab • Pascolizumab • Pateclizumab • Pembrolizumab (+beraialuronidasi alfa) • Pexelizumab • Pidilizumab • Plozalizumab • Quilizumab • Ravulizumab • Reslizumab • Rontalizumab • Rovelizumab • Ruplizumab • Samalizumab • Satralizumab • Siplizumab • Spartalizumab† • Talizumab • Teclistamab • Teplizumab • Tocilizumab • Toralizumab • Tregalizumab • Vatelizumab • Vedolizumab • Visilizumab • Vobarilizumab • Theralizumab§
Attivazione immunitaria: Dostarlimab
Altri: Ibalizumab†
|
|---|
| Chimerici + umanizzati | Dorlixizumab • Otelixizumab • Rozanolixizumab • Sutimlimab |
|---|
